Dr. Nipun Verma
@drnipunverma.bsky.social
Clinician Hepatologist dedicated to patient care, teaching and research..
Excellent study
March 26, 2025 at 12:16 AM
Excellent study
March 7, 2025 at 4:09 PM
💡 Should NAD patients be prioritized for earlier intervention? Could targeting necroptosis & pyroptosis prevent disease progression?
March 7, 2025 at 4:09 PM
💡 Should NAD patients be prioritized for earlier intervention? Could targeting necroptosis & pyroptosis prevent disease progression?
🔬 Key findings:
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
March 7, 2025 at 4:09 PM
🔬 Key findings:
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
Excellent summary and discussion Dr Atoosa..💐Thanks for your presentation
March 1, 2025 at 9:25 AM
Excellent summary and discussion Dr Atoosa..💐Thanks for your presentation
Reposted by Dr. Nipun Verma
🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10....
#LiverSky
#LiverSky
A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis - Journal of Translational Medicine
Background Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predictin...
translational-medicine.biomedcentral.com
December 19, 2024 at 9:40 AM
🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10....
#LiverSky
#LiverSky